The Biliary Stenting Strategy for the Unresectable Hilar Type of Intrahepatic Cholangiocarcinoma: A Single‐Center Experience
Journal of Digestive Diseases · 2025
DOI: 10.1111/1751-2980.13350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Digestive Diseases, 2025. Verfasst von Cui Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Eastern Hepatobiliary Surgery Hospital, Naval Military Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Stents, Klatskin Tumor, Cholangiocarcinoma. Die Arbeit nennt 30 Literaturangaben. Gefördert von: 2024 the Third Hospital Affiliated to Naval Medical University Ascend Talent Project.
Abstract (Originalsprache)
Objectives
Hilar‐type intrahepatic cholangiocarcinoma (H‐ICC), which originates from the large bile ducts, tends to invade the hepatic hilus and results in malignant hilar biliary obstruction (MHBO). Compared with hilar cholangiocarcinoma (HC), H‐ICC exhibits a more aggressive biological behavior and a dismal prognosis. We aimed to investigate the optimal biliary stenting strategy for the treatment of unresectable H‐ICC.
Methods
Patients with unresectable H‐ICC who received endoscopic biliary stenting (EBS) between January 2012 and June 2019 were retrospectively included in this study. The prognostic factors of survival outcome, clinical success, duration of stent patency, and EBS‐related adverse events were analyzed.
Results
Altogether 70 patients were enrolled, including 72.9% patients with multiple intrahepatic lesions and 44.3% with lymphatic metastasis. Jaundice control was achieved in 81.4% of the patients. Early cholangitis was the main treatment‐related complication (17.1%). After successful stenting, systematic antitumor therapy was the only independent factor related to overall survival (hazard ratio [HR] 0.381, 95% confidence interval [CI] 0.218–0.668, p = 0.001). Plastic stenting was associated with clinical success (odds ratio [OR] 0.012, 95% CI 0.008–0.549, p = 0.012), stent patency (HR 6.773, 95% CI 2.221–20.653, p = 0.001), and early cholangitis (OR 5.000, 95% CI 1.006–24.841, p = 0.049). Bismuth classification IV was independently related to stent patency (HR 4.956, 95% CI 1.245–19.730, p = 0.023).
Conclusion
For H‐ICC‐induced MHBO, metal stent placement may achieve better biliary drainage and, combined with systemic antitumor therapies, may further improve patient survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Eastern Hepatobiliary Surgery Hospital, Naval Military Medical University, Shanghai, China.
- Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, China.
ORCID-Profile: Wen Chao Zhao, Bing Hu
Förderung
- 2024 the Third Hospital Affiliated to Naval Medical University Ascend Talent Project
Zitieren
APA
Chen, C., Zhao, W. C., Xia, M. X., Zhu, J. H., Fu, T. T., Wu, J., Yao, Z. Y., & Hu, B. (2025). The Biliary Stenting Strategy for the Unresectable Hilar Type of Intrahepatic Cholangiocarcinoma: A Single‐Center Experience. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.13350
Vancouver
Chen C, Zhao WC, Xia MX, Zhu JH, Fu TT, Wu J, et al. The Biliary Stenting Strategy for the Unresectable Hilar Type of Intrahepatic Cholangiocarcinoma: A Single‐Center Experience. Journal of Digestive Diseases. 2025. doi:10.1111/1751-2980.13350
BibTeX
@article{Chen2025,
author = {Chen, Cui and Zhao, Wen Chao and Xia, Ming Xing and Zhu, Jia Hui and Fu, Ting Ting and Wu, Jun and Yao, Zhi Yuan and Hu, Bing},
title = {The Biliary Stenting Strategy for the Unresectable Hilar Type of Intrahepatic Cholangiocarcinoma: A Single‐Center Experience},
journal = {Journal of Digestive Diseases},
year = {2025},
doi = {10.1111/1751-2980.13350}
}
EUVIMED